Globe Newswire06.26.19
AVRA Medical Robotics Inc., an emerging company creating the next generation of autonomous surgical robotics through the use of technologies such as artificial intelligence, machine learning and proprietary medical software architecture, has retained The Horizon Phoenix Group and its principal, Timothy K. Duggins, as a regulatory consultant. The company entered into a four-year contract to conduct regulatory work on behalf of AVRA.
The Horizon Phoenix Group has commenced its services on behalf of AVRA and has since initiated a dialogue with the U.S. Food and Drug Administration (FDA), prepared and filed an application for AVRA’s fully autonomous surgical robotic system with the FDA. With the application filed, the company has proceeded to request its first meeting with the FDA.
Duggins, said, “I’m extremely excited to join AVRA as their regulatory consultant. In my 35 years of assisting companies and helping them pursue their commercialization goals, I have never seen as promising a technology as AVRA’s fully autonomous surgical robotic platform, which has all the hallmarks to becoming a game-changer in the medical industry. I believe that the path to commercialization is within reach for AVRA and am looking forward to helping the company bring their new technologies to the healthcare marketplace.”
Barry Cohen, Chairman and CEO of AVRA, said, “We are extremely pleased to retain Tim and his firm, The Horizon Phoenix Group, to assist AVRA pursue the FDA approval for our first-generation robotic arm including software that will ultimately make the robotic arm function autonomously. Tim is a seasoned professional and is highly regarded in the industry. In addition to his deep expertise in the industry, Tim received the Best Abstract Award at the 3rd World Congress on Clinical Trials in Vienna, Austria. I’m grateful to have Tim at our side and believe he will keep us on the right track in pursuing the necessary approvals to obtain commercialization in a timely fashion.”
AVRA Medical Robotics Inc. is transforming the practice of medicine by developing a fully autonomous surgical robotic system that “robotizes” a wide range of medical procedures currently being performed by human hands using surgical and non-surgical devices and instruments. AVRA is concentrating its research and development efforts to meet rising expectations of patients and practitioners alike for the precision, safety and speed offered by robotics and artificial intelligence as well as proprietary medical software architecture when combined with proven medical devices and surgical instruments.
The Horizon Phoenix Group has commenced its services on behalf of AVRA and has since initiated a dialogue with the U.S. Food and Drug Administration (FDA), prepared and filed an application for AVRA’s fully autonomous surgical robotic system with the FDA. With the application filed, the company has proceeded to request its first meeting with the FDA.
Duggins, said, “I’m extremely excited to join AVRA as their regulatory consultant. In my 35 years of assisting companies and helping them pursue their commercialization goals, I have never seen as promising a technology as AVRA’s fully autonomous surgical robotic platform, which has all the hallmarks to becoming a game-changer in the medical industry. I believe that the path to commercialization is within reach for AVRA and am looking forward to helping the company bring their new technologies to the healthcare marketplace.”
Barry Cohen, Chairman and CEO of AVRA, said, “We are extremely pleased to retain Tim and his firm, The Horizon Phoenix Group, to assist AVRA pursue the FDA approval for our first-generation robotic arm including software that will ultimately make the robotic arm function autonomously. Tim is a seasoned professional and is highly regarded in the industry. In addition to his deep expertise in the industry, Tim received the Best Abstract Award at the 3rd World Congress on Clinical Trials in Vienna, Austria. I’m grateful to have Tim at our side and believe he will keep us on the right track in pursuing the necessary approvals to obtain commercialization in a timely fashion.”
AVRA Medical Robotics Inc. is transforming the practice of medicine by developing a fully autonomous surgical robotic system that “robotizes” a wide range of medical procedures currently being performed by human hands using surgical and non-surgical devices and instruments. AVRA is concentrating its research and development efforts to meet rising expectations of patients and practitioners alike for the precision, safety and speed offered by robotics and artificial intelligence as well as proprietary medical software architecture when combined with proven medical devices and surgical instruments.
